HUP0002070A2 - Alternatively targeted adenovirus - Google Patents

Alternatively targeted adenovirus

Info

Publication number
HUP0002070A2
HUP0002070A2 HU0002070A HUP0002070A HUP0002070A2 HU P0002070 A2 HUP0002070 A2 HU P0002070A2 HU 0002070 A HU0002070 A HU 0002070A HU P0002070 A HUP0002070 A HU P0002070A HU P0002070 A2 HUP0002070 A2 HU P0002070A2
Authority
HU
Hungary
Prior art keywords
adenovirus
adenoviruses
native
receptor
subject
Prior art date
Application number
HU0002070A
Other languages
Hungarian (hu)
Inventor
Douglas E. Brough
David Einfeld
Imre Kovesdi
Alena Lizonova
Petrus W. Roelvink
Thomas J. Wickham
Grant Yonehiro
Original Assignee
Genvec, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genvec, Inc. filed Critical Genvec, Inc.
Publication of HUP0002070A2 publication Critical patent/HUP0002070A2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C12N2810/405—Vectors comprising RGD peptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/50—Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/80—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates
    • C12N2810/85—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian
    • C12N2810/855—Vectors comprising as targeting moiety peptide derived from defined protein from vertebrates mammalian from receptors; from cell surface antigens; from cell surface determinants

Abstract

A találmány tárgyát alternatív módon célba juttatott adenovírusképezi, továbbá eljárások ilyen vírusok előállítására és tisztítására,valamint ilyen alternatív célba juttatást lehetővé tevőproteinmódosítások. Közelebbről, a találmány tárgyát egy trimerrészecske képezi, amely három monomert tartalmaz, amelyek mindegyikeadenovírus-fiberprotein amino-terminusát és trimerizációs doménttartalmaz. A trimer kisebb affinitást mutat natív szubsztráttalszemben, mint a natív adenovírus fibertrimerek. A találmány tárgyátképezi továbbá, a találmány szerinti trimert tartalmazó adenovírus ésmódosított penton. Ezen felül a találmány tárgyát képezi egy olyan nemnatív sejtfelszíni receptort expresszáló sejtvonal, mely receptorhoz areceptor ligandumát hordozó adenoví-rusok kötődnek, továbbá eljárásadenovírusok szaporítására a sejtvonal alkalmazásával. A találmányszerinti megoldás alkalmas adenovírus-fertőzések kezelését ésmegelőzését célzó eljárások kidolgozására. ÓThe subject of the invention is alternatively targeted adenoviruses, as well as methods for the production and purification of such viruses, as well as protein modifications enabling such alternative targeting. More specifically, the invention relates to a trimeric particle comprising three monomers, each containing the amino terminus and trimerization domain of adenovirus fiber protein. The trimer shows a lower affinity for the native substrate than the native adenovirus fibertrimers. The invention also includes the adenovirus containing the trimer according to the invention and modified penton. In addition, the subject of the invention is a cell line expressing a non-native cell surface receptor, to which receptor adenoviruses carrying a receptor ligand bind, and a method for propagating adenoviruses using the cell line. The solution according to the invention is suitable for the development of procedures aimed at the treatment and prevention of adenovirus infections. HE

HU0002070A 1997-05-28 1998-05-28 Alternatively targeted adenovirus HUP0002070A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US4784997P 1997-05-28 1997-05-28
US7166898P 1998-01-16 1998-01-16
PCT/US1998/011024 WO1998054346A1 (en) 1997-05-28 1998-05-28 Alternatively targeted adenovirus

Publications (1)

Publication Number Publication Date
HUP0002070A2 true HUP0002070A2 (en) 2000-10-28

Family

ID=26725500

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0002070A HUP0002070A2 (en) 1997-05-28 1998-05-28 Alternatively targeted adenovirus

Country Status (10)

Country Link
EP (1) EP0988390A1 (en)
JP (1) JP2001518806A (en)
BR (1) BR9809173A (en)
CA (1) CA2291323A1 (en)
HU (1) HUP0002070A2 (en)
IL (1) IL133010A0 (en)
NZ (1) NZ501140A (en)
PL (1) PL337130A1 (en)
SK (1) SK159999A3 (en)
WO (1) WO1998054346A1 (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002525065A (en) * 1998-09-11 2002-08-13 ジェンベク、インコーポレイティッド Adenoviruses selectively targeted
US6649396B1 (en) * 1999-02-05 2003-11-18 Uab Research Foundation Fiber receptor-independent system for the propagation of adenoviral vectors
JP2000279178A (en) * 1999-02-24 2000-10-10 Japan Found Cancer Res Virus vector
EP1593742A3 (en) * 1999-06-01 2006-02-01 The University of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection
ATE291633T1 (en) * 1999-06-01 2005-04-15 Univ Washington RECOMBINANT ADENOVIRAL VECTORS EXPRESSING CHIMERIC FIBER PROTEINS FOR CELL-SPECIFIC INFECTION AND GENOMIC INTEGRATION
US7094398B1 (en) 1999-06-01 2006-08-22 University Of Washington Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
DK1272507T3 (en) 2000-04-12 2005-10-03 Amersham Health As Integrin-binding peptide derivatives
CA2407518A1 (en) * 2000-04-26 2001-11-01 Crucell Holland B.V. Adenovirus vectors with knobless fibers, and their uses
EP1167533A1 (en) * 2000-06-23 2002-01-02 Vereniging Voor Christelijk Wetenschappelijk Onderwijs Methods and means for the complementation of viral protein expression in stable cell lines
GB0017720D0 (en) 2000-07-19 2000-09-06 Got A Gene Ab Modified virus
NO20004795D0 (en) 2000-09-26 2000-09-26 Nycomed Imaging As Peptide-based compounds
PL207834B1 (en) 2001-07-10 2011-02-28 Ge Healthcare As Peptide-based compounds
FR2842823A1 (en) * 2002-07-25 2004-01-30 Inst Nat Sante Rech Med MODIFIED ADENOVIRUSES FOR TARGETING B-LYMPHOCYTES
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
JP2007525166A (en) 2003-03-28 2007-09-06 ザ・スクリップス・リサーチ・インスティテュート Adenovirus particles with increased infectivity to dendritic cells and particles with reduced infectivity to hepatocytes
ATE458500T1 (en) 2003-11-14 2010-03-15 Genvec Inc PHARMACEUTICAL COMPOUND FOR THE TREATMENT OF LOCALLY ADVANCED PRIMARY INOPERABLE PANCREATIC CARCINOMA (LAPC).
CN1972958B (en) 2004-04-12 2013-01-23 美国政府卫生与公共服务部 Method of using adenoviral vectors to induce an immune response
BRPI0615400A2 (en) 2005-08-31 2011-05-17 Genvec Inc adenoviral vector-based malaria vaccines
BRPI0618441B8 (en) 2005-11-10 2021-07-27 Genvec Inc adenoviral vector
WO2007094653A1 (en) * 2006-02-13 2007-08-23 Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg Adenovirus particles having a chimeric adenovirus spike protein, use thereof and methods for producing such particles.
EP2374002A1 (en) 2008-12-23 2011-10-12 GE Healthcare UK Limited Application of 99mtc peptide-based compound as a bone marrow imaging agent
EP2248903A1 (en) 2009-04-29 2010-11-10 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted gene transfer to monocytes and macrophages
US20120219583A1 (en) 2009-10-16 2012-08-30 Los Alamos National Security, Llc Nucleic acid sequences encoding expandable hiv mosaic proteins
WO2011057254A2 (en) 2009-11-09 2011-05-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Simian adenoviral vector-based vaccines
WO2011057248A2 (en) 2009-11-09 2011-05-12 Genvec, Inc. Simian adenovirus and methods of use
WO2012021730A2 (en) 2010-08-11 2012-02-16 Genvec, Inc. Respiratory syncytial virus (rsv) vaccine
WO2012083297A2 (en) 2010-12-17 2012-06-21 Genvec, Inc. Adenoviral vectors with modified hexon regions
EP2654786B1 (en) 2010-12-20 2019-02-20 GenVec, Inc. Adenoviral vector-based dengue fever vaccine
WO2013181128A1 (en) 2012-05-29 2013-12-05 Genvec, Inc. Modified serotype 28 adenoviral vectors
KR102089121B1 (en) 2013-03-14 2020-03-13 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 Oncolytic adenovirus compositions
TWI710635B (en) 2014-10-09 2020-11-21 美商珍維克公司 Adenoviral vector encoding human atonal homolog-1 (hath1)
EP3072900A1 (en) * 2015-03-27 2016-09-28 Medizinische Hochschule Hannover Anti-tumour medicament based on adenovirus
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
CA3038968A1 (en) 2016-09-30 2018-04-05 Genvec, Inc. Adenovectors for delivery of therapeutic genetic material into t cells
JP2019536468A (en) 2016-12-12 2019-12-19 ソーク インスティテュート フォー バイオロジカル スタディーズ Synthetic adenovirus targeting tumors and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4851341A (en) * 1986-12-19 1989-07-25 Immunex Corporation Immunoaffinity purification system
GB9223084D0 (en) * 1992-11-04 1992-12-16 Imp Cancer Res Tech Compounds to target cells
US5846782A (en) * 1995-11-28 1998-12-08 Genvec, Inc. Targeting adenovirus with use of constrained peptide motifs
US5559099A (en) * 1994-09-08 1996-09-24 Genvec, Inc. Penton base protein and methods of using same
US5770442A (en) * 1995-02-21 1998-06-23 Cornell Research Foundation, Inc. Chimeric adenoviral fiber protein and methods of using same

Also Published As

Publication number Publication date
PL337130A1 (en) 2000-07-31
CA2291323A1 (en) 1998-12-03
SK159999A3 (en) 2000-06-12
IL133010A0 (en) 2001-03-19
WO1998054346A1 (en) 1998-12-03
JP2001518806A (en) 2001-10-16
BR9809173A (en) 2000-08-01
NZ501140A (en) 2001-07-27
EP0988390A1 (en) 2000-03-29

Similar Documents

Publication Publication Date Title
HUP0002070A2 (en) Alternatively targeted adenovirus
DE69637545D1 (en) CHIMERIC ADENOVIRAL FIBER PROTEIN AND METHOD OF USE THEREOF
HUP0102612A2 (en) Modulators of protein tyrosine phosphatases
ATE328891T1 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT AND DIAGNOSIS OF IMMUNE DISORDERS
IS4754A (en) Genes and methods for gene transfer into cells
NO20043245L (en) Binding proteins as biosensors
HUP0203567A2 (en) April receptor (bcma) and uses thereof
GEP20135981B (en) Erythropoietin receptor peptide formulations and usage thereof
BR9814276A (en) Surface antigens
ATE382695T1 (en) TARGETING ADENOVIRUSES USING CONFORMATION-RESTRICTED PEPTIDE MOTIVES
ATE421584T1 (en) CPG RECEPTOR (CPG-R) AND RELATED METHODS
WO2003016475A3 (en) Nucleic acid and amino acid sequences involved in pain
PT1083903E (en) INDENOPROLOCARBAZOLES IN BRIDGE
WO2003054005A3 (en) Bone polypeptide-1
WO2004005481A3 (en) Methods for identifying modulators of mda-7 mediated apoptosis
WO2004113500A3 (en) B7s1: an immune modulator
DE60031994D1 (en) KAPSIDE-MODIFIED RECOMBINANT ADENOVIRUS AND METHOD FOR THE APPLICATION THEREOF
WO1998011234A3 (en) Human protein kinases
FI972170A (en) Peptides capable of binding to the SH3 domain of the GAP protein, nucleotide sequences encoding these peptides, their preparation and use
WO2004003172A3 (en) Esm-1 gene differentially expressed in angiogenesis, antagonists thereof, and methods of using the same
AU2003235799A1 (en) Modulation of iamt (pimt or pcmt) in immune system
DK1051491T3 (en) Equin Fc Epsilon receptor alpha chain nucleic acid molecules, corresponding proteins and their use
DE69840326D1 (en) INCREASING IMMUNE RESPONSE USING TARGETED MOLECULES
DK0981601T3 (en) Methods for culturing cells and propagating viruses
TR200100430T2 (en) Useful methods and compositions for modulation of angiogenesis using Tyrosine kinase SRC.